In silico and in vitro evaluation of designed fluconazole analogues as lanosterol 14α-demethylase inhibitors

References

• Al-Baqsami, Z. F., Ahmad, S., & Khan, Z. (2020). Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait. Scientific Reports, 10(1), 6238. https://doi.org/10.1038/s41598-020-63240-z
   PubMed Web of Science ®Google Scholar
• Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A. W., Baldassarri, I., Rinaldi, M. G., & Scalise, G. (2004). In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrobial Agents and Chemotherapy, 48(9), 3317–3322. https://doi.org/10.1128/AAC.48.9.3317-3322.2004
   PubMed Web of Science ®Google Scholar
• Bhardwaj, V. K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., & Kumar, S. (2021). Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. Journal of Biomolecular Structure & Dynamics, 39(10), 3449–3458. https://doi.org/10.1080/07391102.2020.1766572
   PubMed Web of Science ®Google Scholar
• Bibi, Z. (2008). Role of cytochrome P450 in drug interactions. Nutrition & Metabolism, 5(1), 27. https://doi.org/10.1186/1743-7075-5-27
   PubMedGoogle Scholar
• Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O., & Burke, D. (2006). Structural biology and bioinformatics in drug design: Opportunities and challenges for target identification and lead discovery. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 361(1467), 413–423. https://doi.org/10.1098/rstb.2005.1800
   PubMed Web of Science ®Google Scholar
• Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990). Pharmacokinetics and tissue penetration of fluconazole in humans. Reviews of Infectious Diseases, 12, 318–327.
   PubMedGoogle Scholar
• Brüggemann, R. J. M., Alffenaar, J.-W C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009). Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases, 48(10), 1441–1458. https://doi.org/10.1086/598327
   PubMed Web of Science ®Google Scholar
• Cha, R., & Sobel, J. D. (2004). Fluconazole for the treatment of candidiasis: 15 years experience. Expert Review of Anti-Infective Therapy, 2(3), 357–366. https://doi.org/10.1586/14787210.2.3.357
   PubMedGoogle Scholar
• Chai, X., Zhang, J., Yu, S., Hu, H., Zou, Y., Zhao, Q., Dan, Z., Zhang, D., & Wu, Q. (2009). Design, synthesis, and biological evaluation of novel 1-(1H-1, 2, 4-triazole-1-yl)-2-(2, 4-difluorophenyl)-3-substituted benzylamino-2-propanols. Bioorganic & Medicinal Chemistry, 19(6), 1811–1814. https://doi.org/10.1016/j.bmcl.2009.01.048
   Web of Science ®Google Scholar
• Chandrika, N. T., Shrestha, S. K., Ngo, H. X., Howard, K. C., & Garneau-Tsodikova, S. (2018). Novel fluconazole derivatives with promising antifungal activity. Bioorganic & Medicinal Chemistry, 26(3), 573–580. https://doi.org/10.1016/j.bmc.2017.12.018
   PubMed Web of Science ®Google Scholar
• Chaturvedi, V., Ramani, R., Andes, D., Diekema, D. J., Pfaller, M. A., Ghannoum, M. A., Knapp, C., Lockhart, S. R., Ostrosky-Zeichner, L., Walsh, T. J., Marchillo, K., Messer, S., Welshenbaugh, A. R., Bastulli, C., Iqbal, N., Paetznick, V. L., Rodriguez, J., & Sein, T. (2011). Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrobial Agents and Chemotherapy, 55(4), 1543–1548. https://doi.org/10.1128/AAC.01510-09
   PubMed Web of Science ®Google Scholar
• Chen, J., & Shen, B. (2009). Computational Analysis of amino acid mutation: A proteome wide perspective. Current Proteomics, 6(4), 228–234. https://doi.org/10.2174/157016409789973734
   Web of Science ®Google Scholar
• CLSI. (2002). Performance standards for antifungal susceptibility testing of yeasts. CLSI Supplement M60. (1st ed.). Clinical and Laboratory Standards.
   Google Scholar
• CLSI. (2017). Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI Standard M27 (4th ed.). Clinical and Laboratory Standards.
   Google Scholar
• Dallakyan, S., & Olson, A. J. (2015). Small-molecule library screening by docking with PyRx. Methods in Molecular Biology (Clifton, N.J.), 1263, 243–250. https://doi.org/10.1007/978-1-4939-2269-7_19
   PubMedGoogle Scholar
• Dangi, M., Khichi, A., Jakhar, R., & Chhillar, A. K. (2021). Growing preferences towards Analog-based drug discovery. Current Pharmaceutical Biotechnology, 22(8), 1030–1045. https://doi.org/10.2174/1389201021666200908121409
   PubMed Web of Science ®Google Scholar
• Dutta, K., Elmezayen, A. D., Al-Obaidi, A., Zhu, W., Morozova, O. V., Shityakov, S., & Khalifa, I. (2021). Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations. Journal of Molecular Structure, 1246, 131113. https://doi.org/10.1016/j.molstruc.2021.131113
   PubMed Web of Science ®Google Scholar
• Emami, S., Ghobadi, E., Saednia, S., & Hashemi, S. M. (2019). Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies. European Journal of Medicinal Chemistry, 170, 173–194. https://doi.org/10.1016/j.ejmech.2019.03.020
   PubMed Web of Science ®Google Scholar
• Fattouh, N., Hdayed, D., Geukgeuzian, G., Tokajian, S., & Khalaf, R. A. (2021). Molecular mechanism of fluconazole resistance and pathogenicity attributes of Lebanese Candida albicans hospital isolates. Fungal Genetics and Biology, 153, 103575. https://doi.org/10.1016/j.fgb.2021.103575
   PubMed Web of Science ®Google Scholar
• Forli, S., Huey, R., Pique, M. E., Sanner, M. F., Goodsell, D. S., & Olson, A. J. (2016). Computational protein–ligand docking and virtual drug screening with the AutoDock suite. Nature Protocols, 11(5), 905–919. https://doi.org/10.1038/nprot.2016.051
   PubMed Web of Science ®Google Scholar
• Ghorab, M. M., Alsaid, M. S., Al-Ansary, G. H., Abdel-Latif, G. A., & Abou El Ella, D. A. (2016). Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers. European Journal of Medicinal Chemistry, 124, 946–958. https://doi.org/10.1016/j.ejmech.2016.10.020
   PubMed Web of Science ®Google Scholar
• Giraud, F., Loge, C., Pagniez, F., Crepin, D., Pape, P. L., & Borgne, M. L. (2008). Design, synthesis, and evaluation of 1-(N-benzylamino)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. Bioorganic & Medicinal Chemistry Letters, 18(6), 1820–1824. https://doi.org/10.1016/j.bmcl.2008.02.027
   PubMed Web of Science ®Google Scholar
• Goa, K. L., & Barradell, L. B. (1995). Fluconazole. An update of its Pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs, 50(4), 658–690. https://doi.org/10.2165/00003495-199550040-00007
   PubMed Web of Science ®Google Scholar
• Guillon, R., Pagniez, F., Giraud, F., Crépin, D., Picot, C., Le Borgne, M., Morio, F., Duflos, M., Logé, C., & Le Pape, P. (2011). Design, synthesis, and in vitro antifungal activity of 1-[(4-substituted-benzyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols. ChemMedChem. 6(5), 816–825. https://doi.org/10.1002/cmdc.201000530
   PubMed Web of Science ®Google Scholar
• Jakhar, R., Khichi, A., Kumar, D., Dangi, M., & Chhillar, A. K. (2022). Discovery of novel inhibitors of bacterial DNA gyrase using a QSAR-Based Approach. ACS Omega, 7(36), 32665–32678. https://doi.org/10.1021/acsomega.2c04310
   PubMed Web of Science ®Google Scholar
• Johansson, M. U., Zoete, V., Michielin, O., & Guex, N. (2012). Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics, 13, 173. https://doi.org/10.1186/1471-2105-13-173
   PubMed Web of Science ®Google Scholar
• Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020). Fungal infections in humans: The silent crisis. Microbial Cell (Graz, Austria), 7(6), 143–145. https://doi.org/10.15698/mic2020.06.718
   PubMed Web of Science ®Google Scholar
• Khalifa, H. O., Majima, H., Watanabe, A., & Kamei, K. (2021). In vitro characterization of twenty-one antifungal combinations against echinocandin-resistant and -susceptible Candida glabrata. Journal of Fungi (Basel), 7(2), 1-15. https://doi.org/10.3390/jof7020108
   PubMedGoogle Scholar
• Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3(8), 711–715. https://doi.org/10.1038/nrd1470
   PubMed Web of Science ®Google Scholar
• Lebouvier, N., Pagniez, F., Duflos, M., Pape, L. P., Na, Y. M., Baut, L. G., & Borgne, L. M. (2007). Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. Bioorganic & Medicinal Chemistry Letters, 17(13), 3686–3689. https://doi.org/10.1016/j.bmcl.2007.04.038
   PubMed Web of Science ®Google Scholar
• Lewis, R. E., Diekema, D. J., Messer, S. A., Pfaller, M. A., & Klepser, M. E. (2002). Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. The Journal of Antimicrobial Chemotherapy, 49(2), 345–351. https://doi.org/10.1093/jac/49.2.345
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3–26. https://doi.org/10.1016/s0169-409x(00)00129-0
   PubMed Web of Science ®Google Scholar
• Liu, P., Zhu, S., Li, P., Xie, W., Jin, Y., Sun, Q., Wu, Q., Sun, P., Zhang, Y., Yang, X., Jiang, Y., & Zhang, D. (2008). Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents. Bioorganic & Medicinal Chemistry Letters, 18(11), 3261–3265. https://doi.org/10.1016/j.bmcl.2008.04.056
   PubMed Web of Science ®Google Scholar
• Maurya, A. K., Mulpuru, V., & Mishra, N. (2020). Discovery of novel coumarin analogs against the α-glucosidase protein target of diabetes mellitus: Pharmacophore-based QSAR, docking, and molecular dynamics simulation studies. ACS Omega. 5(50), 32234–32249. https://doi.org/10.1021/acsomega.0c03871
   PubMed Web of Science ®Google Scholar
• McDonnell, A. M., & Dang, C. H. (2013). Basic review of the cytochrome p450 system. Journal of the Advanced Practitioner in Oncology, 4(4), 263–268.
   PubMedGoogle Scholar
• Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. The Journal of Antimicrobial Chemotherapy, 52(1), 1. https://doi.org/10.1093/jac/dkg301
   PubMed Web of Science ®Google Scholar
• Padmanabhan, S. (2014). Handbook of pharmacogenomics and stratified medicine. Elsevier Science.
   Google Scholar
• Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E, Infectious Diseases Society of America. (2004). Practice guidelines for the treatment of candidiasis. Clinical Infectious Diseases, 38(2), 161–189. https://doi.org/10.1086/380796
   PubMed Web of Science ®Google Scholar
• Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews. Drug Discovery, 9(3), 203–214. https://doi.org/10.1038/nrd3078
   PubMed Web of Science ®Google Scholar
• Pore, V. S., Aher, N. G., Kumar, M., & Shukla, P. K. (2006). Design and synthesis of fluconazole/bile acid conjugate using click reaction. Tetrahedron, 62(48), 11178–11186. https://doi.org/10.1016/j.tet.2006.09.021
   Web of Science ®Google Scholar
• Prakash, S. M. U., & Kabir, M. A. (2022). Repurposing vilanterol as a novel potential antifungal for Candida albicans: In-silico & in-vitro approach. Medicine in Drug Discovery, 15, 100137. https://doi.org/10.1016/j.medidd.2022.100137
   Google Scholar
• Rafi, M. O., Bhattacharje, G., Al-Khafaji, K., Taskin-Tok, T., Alfasane, M. A., Das, A. K., Parvez, M. A. K., & Rahman, M. S. (2022). Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: Analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. Journal of Biomolecular Structure & Dynamics, 40(8), 3711–3730. https://doi.org/10.1080/07391102.2020.1850355
   PubMed Web of Science ®Google Scholar
• Rolta, R., Salaria, D., Sharma, P., Sharma, B., Kumar, V., Rathi, B., Verma, M., Sourirajan, A., Baumler, D. J., & Dev, K. (2021). Phytocompounds of Rheum emodi, Thymus serpyllum, and Artemisia annua inhibit spike protein of SARS-CoV-2 binding to ACE2 receptor: In silico approach. Current Pharmacology Reports, 7(4), 135–149. https://doi.org/10.1007/s40495-021-00259-4
   PubMedGoogle Scholar
• Shafiei, M., Toreyhi, H., Firoozpour, L., Akbarzadeh, T., Amini, M., Hosseinzadeh, E., Hashemzadeh, M., Peyton, L., Lotfali, E., & Foroumadi, A. (2021). Design, synthesis, and in vitro and in vivo evaluation of novel fluconazole-based compounds with promising antifungal activities. ACS Omega, 6(38), 24981–25001. https://doi.org/10.1021/acsomega.1c04016
   PubMed Web of Science ®Google Scholar
• Sheng, C., Wang, W., Che, X., Dong, G., Wang, S., Ji, H., Miao, Z., Yao, J., & Zhang, W. (2010). Improved model of lanosterol 14α-demethylase by ligand-supported homology modeling: Validation by virtual screening and azole optimization. ChemMedChem, 5(3), 390–397. https://doi.org/10.1002/cmdc.200900468
   PubMed Web of Science ®Google Scholar
• Singh, J., Sangwan, N., Chauhan, A., & Avti, P. K. (2022). Integrative network and computational simulation of clinical and genomic data for the identification of mutated EGFR in breast cancer patients for therapeutic targeting using purine analogues. Molecular Simulation, 48(17), 1548–1560. https://doi.org/10.1080/08927022.2022.2107638
   Web of Science ®Google Scholar
• Sliwoski, G., Kothiwale, S. K., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334–395. https://doi.org/10.1124/pr.112.007336
   PubMed Web of Science ®Google Scholar
• Wadood, A., Ahmed, N., Shah, L., Ahmad, A., Hassan, H., & Shams, S. (2013). In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery, 1(1), 3.
   Google Scholar
• Wang, S., Jin, G., Wang, W., Zhu, L., Zhang, Y., Dong, G., Liu, Y., Zhuang, C., Miao, Z., Yao, J., Zhang, W., & Sheng, C. (2012). Design, synthesis and structure–activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains. European Journal of Medicinal Chemistry, 53, 292–299. https://doi.org/10.1016/j.ejmech.2012.04.013
   PubMed Web of Science ®Google Scholar
• Wang, W., Lei, X., Ai, H. L., Bai, X., Li, J., He, J., Li, Z. H., Zheng, Y. S., Feng, T., & Liu, J. K. (2019). Cytochalasans from the endophytic fungus Xylaria cf. curta with resistance reversal activity against fluconazole-resistant Candida albicans. Organic Letters, 21(4), 1108–1111. https://doi.org/10.1021/acs.orglett.9b00015
   PubMed Web of Science ®Google Scholar
• Wang, E. J., Lew, K., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2002). Interaction of common azole antifungals with P glycoprotein. Antimicrobial Agents and Chemotherapy, 46(1), 160–165. https://doi.org/10.1128/AAC.46.1.160-165.2002
   PubMed Web of Science ®Google Scholar
• Wang, W., Sheng, C., Che, X., Ji, H., Cao, Y., Miao, Z., Yao, J., & Zhang, W. (2009). Discovery of highly potent novel antifungal azoles by structure-based rational design. Bioorganic & Medicinal Chemistry Letters, 19(20), 5965–5969. https://doi.org/10.1016/j.bmcl.2009.07.144
   PubMed Web of Science ®Google Scholar
• Wang, Y., Xu, K., Bai, G., Huang, L., Wu, Q., Pan, W., & Yu, S. (2014). Synthesis and antifungal activity of novel triazole compounds containing piperazine moiety. Molecules (Basel, Switzerland), 19(8), 11333–11340. https://doi.org/10.3390/molecules190811333
   PubMed Web of Science ®Google Scholar
• Wermuth, C. G. (2006). Similarity in drugs: Reflections on analogue design. Drug Discovery Today, 11(7–8), 348–354. https://doi.org/10.1016/j.drudis.2006.02.006
   PubMed Web of Science ®Google Scholar
• Wishart, D. S. (2005). Bioinformatics in drug development and assessment. Drug Metabolism Reviews, 37(2), 279–310. https://doi.org/10.1081/dmr-55225
   PubMed Web of Science ®Google Scholar
• Xie, F., Hao, Y., Bao, J., Liu, J., Liu, Y., Wang, R., Chi, X., Chai, X., Wang, T., Yu, S., Jin, Y., Yan, L., Zhang, D., & Ni, T. (2022). Design, synthesis, and in vitro evaluation of novel antifungal triazoles containing substituted 1,2,3-triazole-methoxyl side chains. Bioorganic Chemistry, 129, 106216. https://doi.org/10.1016/j.bioorg.2022.106216
   PubMed Web of Science ®Google Scholar
• Yin, W., Zhang, Y., Cui, H., Jiang, H., Liu, L., Zheng, Y., Wu, T., Zhao, L., Sun, Y., Su, X., Li, S., Zhao, D., & Cheng, M. (2021). Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi. European Journal of Medicinal Chemistry, 225, 113740. https://doi.org/10.1016/j.ejmech.2021.113740
   PubMed Web of Science ®Google Scholar